Skip to main content

Table 1 Patients’ baseline characteristics and diagnoses at 2 years follow-up

From: Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany

Variable All (n = 411) Test cohort (n = 329) Validation cohort (n = 82) p value
Mean/% SD Mean/% SD Mean/% SD
Age 56.5 14.6 56.7 14.6 55.7 14.4 0.57
SJC28 6.1 5.4 6.3 5.4 5.4 5.3 0.14
TJC28 9.3 6.0 9.4 5.9 9.0 6.7 0.68
Duration 11.7 7.0 11.8 7.0 11.1 6.8 0.37
CDAI 25.9 12.8 26.2 12.5 24.5 14.1 0.32
CRP 21.6 31.4 21.3 32.2 22.9 28.3 0.67
DAS28 4.6 1.3 4.6 1.3 4.5 1.4 0.42
Female 62.8   61.1   69.5   0.16
ACPA+ 29.4   28.6   32.9   0.44
RF+ 29.4   28.9   31.7   0.62
RA 75.2   76.9   68.3   0.11
Non-RA 24.8   23.1   31.7   1.00
 SpoA 2.9   2.7   3.6   
 PsoA 3.6   3   6.1   
 PMR 0.5   0   2.4   
 CTD 1.9   1.2   4.9   
 uA 15.9   16.2   14.7   
  1. Baseline characteristics and diagnoses at 2 years follow-up of the total cohort, which was randomly split into a test cohort (80%) and a validation cohort (20%). SJC28 28 joint swollen joint count, TJC28 28 joint tender joint count, Duration symptom duration in weeks [wk], CDAI clinical disease activity index, CRP C-reactive protein, ACPA+ anti-citrullinated peptide antibody positive, RF+ IgM rheumatoid factor positive, RA rheumatoid arthritis, SpoA spondyloarthritis, PsoA psoriatic arthritis (not included in SpoA category), PMR polymyalgia rheumatica, CTD connective tissue disease, uA undifferentiated arthritis. p values indicate comparison between test and validation cohorts by T test, Wilcoxon’s test, or Fisher’s exact test, as indicated